Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Core Insights - Lexicon Pharmaceuticals has made significant progress in its pipeline and financial position, with key milestones achieved in 2025 and a strong start to 2026 [2][3] Financial Performance - Total revenues for Q4 2025 were $5.5 million, with annual revenues of $49.8 million, including $4.3 million from licensing revenue and $1.1 million from net sales of INPEFA [12] - The company reported a net loss of $15.5 million for Q4 2025, a reduction from a net loss of $33.8 million in Q4 2024, and a full-year net loss of $50.3 million compared to $200.4 million in 2024 [16] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in 2024, while full-year R&D expenses were $61.1 million, down from $84.5 million [14] - Selling, general and administrative expenses also saw a significant decrease, totaling $8.8 million in Q4 2025 compared to $32.3 million in Q4 2024, and $37.3 million for the full year versus $143.1 million in 2024 [15] Pipeline Developments - Sotagliflozin, an oral SGLT1 and SGLT2 inhibitor, has been studied in approximately 20,000 patients and is commercially available in the U.S. for heart failure as INPEFA [4] - The SONATA-HCM study, a pivotal Phase 3 trial for hypertrophic cardiomyopathy, has surpassed 50% enrollment with a target of 500 patients and is expected to complete enrollment by mid-2026 [8] - Lexicon is on track for a potential NDA resubmission for ZYNQUISTA in Type 1 Diabetes in 2026, contingent on meeting FDA requirements [8] Strategic Partnerships and Funding - The company strengthened its financial position with over $100 million in additional cash from a capital raise and a milestone payment from Novo Nordisk [3][19] - Lexicon has entered into a licensing agreement with Viatris for the commercialization of sotagliflozin outside the U.S. and Europe, with regulatory submissions planned for several markets in 2026 [7][9] Regulatory and Development Readiness - A successful End-of-Phase 2 meeting with the FDA for pilavapadin confirms its readiness for Phase 3 development, which will include placebo-controlled studies [17] - The company is actively engaged in partnership discussions to maximize the global potential of its investigational therapies [17]